QrXPharma board faces spill as it mulls quitting

Embattled pain drug developer QrXPharma has sent mixed messages to the market, urging shareholders to vote against a spill of two directors proposed by disgruntled investor Lang Walker, while also flagging it was considering giving up on its technology.

The company has set a general meeting date of July 7, giving the property development mogul a month to convince shareholders to support the axing of QrXPharma chairman and ResMed founder Peter Farrell and the company’s founder Gary Pace.